Altre lingue Penumbra, Inc.

Azioni

PEN

US70975L1070

Mercato chiuso - Nyse Altri mercati azionari 22:00:02 25/04/2024			Variaz. 5gg	Var. 1 gen.
205,5 ^USD	-0,32%		+1,81%	-18,30%

23/04	Penumbra, Inc. lancia Lightning Flash 2.0 - la più recente tecnologia CAVT progettata per rimuovere rapidamente i coaguli di sangue	CI
28/03	Nyrada inizia lo studio preclinico di buona pratica di laboratorio per il candidato farmaco contro le lesioni cerebrali	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Penumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots	23/04
Penumbra, Inc. Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots	23/04
DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	17/04
EN DIRECTO DESDE LOS MERCADOS: Talgo, Telefónica, Amper, Stellantis, Eni, Amundi, EasyJet, Rheinmetall, Ericsson, Sika, Lockheed, Tesla...	16/04
Penumbra, Inc. : El desvalido de la atención sanitaria	15/04
Penumbra, Inc. : The underdog in healthcare	12/04
Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024	09/04
Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate	28/03
North American Morning Briefing : Traders Await -2-	26/02
Traders Await Fresh Cues After Nvidia-Fueled Rally as US Equity Futures Inch Higher Pre-Bell	23/02
Penumbra Q4 Non-GAAP EPS, Revenue Increase; Shares Fall After-Hours	22/02
Penumbra: Q4 Earnings Snapshot	22/02
Earnings Flash (PEN) PENUMBRA Posts Q4 Revenue $284.7M, vs. Street Est of $286.5M	22/02
Earnings Flash (PEN) PENUMBRA Reports Q4 EPS $0.76, vs. Street Est of $0.70	22/02
Penumbra, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results	22/02
Penumbra, Inc. Provides Earnings Guidance for the Full Year 2024	22/02
Penumbra, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22/02
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 22, 2024	01/02
Penumbra Illuminates Priority Dates Pre And Post-AIA	08/01
Penumbra, Inc. to Present at the J.P. Morgan 42nd Annual Healthcare Conference	19/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Penumbra, Inc.

Azioni

PEN

US70975L1070

Altre lingue

Filtri